Gujarat Magazine

Iron Deficiency Anemia Market Insight, Epidemiology And Market Forecast – 2034

DelveInsight’s “Iron Deficiency Anemia Market Insight, Epidemiology And Market Forecast – 2034” report delivers an in-depth understanding of the iron deficiency anemia treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and iron deficiency anemia market forecasts through 2034, providing crucial insights for stakeholders in the iron deficiency anemia therapeutic area.

According to DelveInsight’s analysis, the iron deficiency anemia treatment market is projected to grow substantially during the forecast period from 2025-2034, driven by enhanced understanding of disease mechanisms and innovative therapeutic approaches.

Download the Iron Deficiency Anemia Market report to understand which factors are driving the iron deficiency anemia therapeutic market trends.

According to DelveInsight’s estimates, the prevalence of anemia was 9.3% in the US population aged 2 years and older, with males having a lower prevalence of anemia than females. In the 7MM, Japan reported the highest prevalent cases of iron deficiency anemia of the total 7MM cases, followed by the US in the year 2024. Among the EU4 and the UK, the highest number of cases of iron deficiency anemia was in the UK and the lowest in France in 2024. In 2024, nearly 1,300 severe cases were estimated across the 7MM, highlighting a significant public health challenge, with projections indicating that this number is poised to rise dramatically by 2034.

The DelveInsight’s report further categorizes the iron deficiency anemia patient population into several main groups for analysis. It differentiates between total prevalent cases, diagnosed prevalent cases, gender-specific diagnosed prevalent cases, pathology-specific diagnosed prevalent cases, severity-specific diagnosed prevalent cases, and total treated cases of iron deficiency anemia. This classification is essential for understanding the distribution, progression, and treatment responses of different iron deficiency anemia severity levels and is crucial for accurate epidemiological assessment.

Discover evolving trends in the Iron Deficiency Anemia patient pool forecasts through comprehensive epidemiological analysis.

Iron deficiency anemia is the most common form of anemia worldwide and is responsible for around 50% of all anemia cases. Currently, the drugs used for the treatment of IDA include AURYXIA (Akebia), INJECTAFER (Vifor), VENOFER (Vifor), FERAHEME (AMAG), FERACCRU (Shield), and others. A significant milestone in iron deficiency anemia treatment occurred with the US FDA approval of AURYXIA from Akebia Therapeutics in November 2017 to address IDA in adults with chronic kidney disease (CKD) who are not on dialysis. AURYXIA is a unique iron-based compound that is non-calcium and non-chewable, distinguished by its chemical properties, with ferric citrate as its active ingredient.

According to the DelveInsight report, the iron deficiency anemia therapies pipeline remains relatively limited in terms of promising candidates, nevertheless, IHAT-02, developed by Nemysis, has successfully progressed to Phase III clinical trials, an important advancement that underscores its strong potential for future regulatory approval. IHAT is a nanoparticulate ferric iron supplement developed to mimic the body’s natural iron absorption mechanisms, modeled after dietary ferritin, an iron-storage protein. With a remarkable 100% success rate among Phase III candidates for IDA, IHAT-02 is positioned as a leading contender for regulatory approval.

Recent developments highlight the dynamic nature of the iron deficiency anemia treatment landscape. In March 2025, Nemysis announced the signing of a Distribution and Supply Agreement for its unique oral iron supplement, IHAT, with Avia Pharma AB, which will act as distributor. As of June 2024, IHAT-02 has advanced to Phase III clinical trials, marking a significant step forward in its development and indicating strong potential for regulatory approval. This innovative formulation addresses common issues such as poor absorption and gastrointestinal side effects, demonstrating superior effectiveness in resolving IDA with fewer side effects than ferrous sulfate or placebo in trials like IHAT-Gut.

Discover recent advancements in the Iron Deficiency Anemia treatment landscape through comprehensive market analysis.

The iron deficiency anemia treatment market is highly competitive, with major players including Akebia Therapeutics, Shield Therapeutics, AMAG Pharmaceuticals, Nemysis, Pharmacosmos Therapeutics, CSL Vifor, American Regent, JW Pharmaceutical, and Zeria Pharmaceutical, all advancing a variety of therapies through robust R&D and strategic collaborations. Key marketed therapies include FERAHEME/RIENSO, FERACCRU/ACCRUFER, MONOFER, AURYXIA, and FERINJECT/INJECTAFER.

Looking ahead, the iron deficiency anemia market is expected to witness continued innovation driven by enhanced understanding of disease mechanisms and the development of novel therapeutic approaches that address current unmet needs. The upcoming therapies for IDA are expected to combat the current unmet needs faced by patients and add to the overall growth of the iron deficiency anemia market size. While significant progress has been made with current iron replacement therapies, challenges remain in addressing gastrointestinal side effects, improving absorption, and enhancing patient tolerability across diverse patient populations.

DelveInsight’s analysis underscores that despite therapeutic advances, substantial opportunities remain for developing more effective, convenient, and affordable treatment options that can achieve optimal iron repletion and improved quality of life for iron deficiency anemia patients worldwide. As research continues and awareness grows, the iron deficiency anemia market is poised for remarkable expansion and therapeutic innovation through 2034.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Iron Deficiency Anemia Market Overview at a Glance

5. Epidemiology and Market Forecast Methodology

6. Key Events

7. Iron Deficiency Anemia Background and Overview

8. Iron Deficiency Anemia Treatment

9. Iron Deficiency Anemia Epidemiology and Patient Population in the 7MM

10. Iron Deficiency Anemia Patient Journey

11. Iron Deficiency Anemia Marketed Drug

12. Iron Deficiency Anemia Emerging Drugs

13. Iron Deficiency Anemia: 7MM Analysis

14. Unmet needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports

Iron Deficiency Anemia Pipeline Insight

Iron Deficiency Anemia Pipeline Insight provides comprehensive insights about the Iron Deficiency Anemia pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Iron Deficiency Anemia companies.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services